David Dolphin is a University Professor Emeritus at the University of British Columbia. He has administrative and research experience in industry, universities and non-governmental organizations. As the Vice-President Technology Development at Quadra Logic Technologies, he was instrumental in the discovery, development and commercialization of Visudyne, which has saved the vision of hundreds of thousands of people afflicted with “wet” age-related macular degeneration. He has served on numerous boards, including as the Chair of Genome British Columbia, the founding chair of the Center for Drug Research and Development and the founding CEO of the BC Innovation Council. He has received numerous awards, including the Prix Galien in 2002, along with Julia Levy and the Hertzberg Medal awarded by NSERC. He is also a fellow of the Royal Society (London). He is an officer of the Order of Canada and a Director of the Alberta Innovates Health Solutions. David is a potter and a member of the Aberthau Potters. He lives just up the hill on 12th Ave.